Humanetics Corporation Presents at the

MedInvest Oncology Investor Conference


Minneapolis, MN - Humanetics Corporation, a clinical-stage pharmaceutical company focused on novel products to improve outcomes for patients with cancer, presented at the MedInvest Oncology Investor Conference being held in New York, NY on December 14-15, 2022.

Ronald J. Zenk, President and Chief Executive Officer, presented a corporate overview and details on its lead drug candidate, BIO 300 at the conference on Thursday, December 15th.  BIO 300 is a new class of drug focused on improving outcomes in cancer patients that received first-line radiotherapy with or without concurrent chemotherapy.  These patients suffer from a myriad of unintended side-effects which can reduce the efficacy of treatment or result in serious toxicities.  BIO 300 acts to protect normal tissues, improving the therapeutic outcome.

BIO 300 is being evaluated in phase 2 clinical trials to prevent normal tissue injury resulting from cancer radiotherapy and to reduce lung damage in COVID-19 long-haul patients. It is self-administered by patients in these trials as an oral liquid nanosuspension. It has shown potential to minimize radiation damage in normal tissues without impacting the effectiveness of the radiation therapy against the tumor. BIO 300 was the recent subject of an early-stage trial in non-small cell lung cancer patients undergoing chemoradiotherapy and was found to be safe, with results pointing to positive clinical outcomes.

Humanetics licensed BIO 300 from the United States Department of Defense (DOD), where it was discovered as a potent radioprotectant for warfighters on the battlefield. Its use in cancer patients is highly aligned with its military use, as it serves in both cases to protect normal tissues from radiation damage.